A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

Inclusion Criteria:

- Histologically documented advanced (Stage IV) or recurrent squamous (Arms A and B) or
non-squamous (Arms C, D, E, and F) non-small cell lung cancer (NSCLC)

- Consent to the collection of an archival formalin-fixed paraffin-embedded (FFPE)
block or freshly cut unstained tumor slides from archival tumor tissue or a newly
collected tumor sample

- ECOG performance status of 0 or 1

- Disease that is measurable per RECIST v1.1

Exclusion Criteria:

- NSCLC with documented EGFR mutation associated with response to EGFR inhibitors or
documented fusion gene involving ALK gene

- Prior therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors,
radiotherapy, immunotherapy, hormonal therapy, or investigational therapy) before Day
1 of Cycle 1 for the treatment of advanced (Stage IV) or recurrent NSCLC

- Known CNS disease except for treated brain metastases

- Type I diabetes

- Type II diabetes requiring chronic therapy with insulin

- Medical conditions that would contraindicate bevacizumab therapy in non-squamous
NSCLC